Trazodone-Induced Vivid Nightmares in Patients

Introduction to Trazodone Side Effects

In a retrospective cohort study of 74 veterans with PTSD, 1 patient (approximately 1.4%) discontinued trazodone due to more vivid nightmares, despite 72% of patients experiencing a beneficial reduction in nightmare frequency from 3.3 to 1.3 nights per week, as reported by the American Academy of Sleep Medicine 1, 2, 3, 4

The nightmare side effect appears to be uncommon but documented, with only 1 out of 74 patients in the primary study reporting this effect, representing a discontinuation rate of approximately 1.4% for this specific side effect, according to the American Academy of Sleep Medicine 2, 3, 4
Trazodone has a broader side effect profile, with 19% of patients discontinuing the medication for various side effects, including priapism and daytime sedation, which were more common reasons than vivid nightmares, as noted by the American Academy of Sleep Medicine 1, 2, 3, 4

Daytime sedation and dizziness are the most frequent side effects, affecting 60% of patients who tolerated the medication, as reported by the American Academy of Sleep Medicine 1, 2, 3, 4
Orthostatic hypotension is a significant concern, particularly in elderly patients, according to the American Academy of Sleep Medicine 2, 3, 4

The American Academy of Sleep Medicine recommends monitoring all patients starting trazodone for any changes in dream content or nightmare frequency, particularly during the first month of treatment, and discontinuing the medication immediately if vivid nightmares develop or worsen 1, 2, 3, 4
Alternative agents such as prazosin (first-line for PTSD-related nightmares) or low-dose doxepin for sleep maintenance may be considered, as suggested by the American Academy of Sleep Medicine and other guideline societies 5

In patients with post‑traumatic stress disorder, approximately 72 % experience a reduction in nightmare frequency, decreasing from an average of 3.3 nights per week to 1.3 nights per week after starting trazodone【6】. (Evidence level not specified)

About 1.4 % of trazodone users discontinue the medication because of newly vivid or distressing nightmares; this figure derives from a cohort of 74 veterans with PTSD, in which 1 patient (1.4 %) stopped treatment for this reason【6】. (Evidence level not specified)
Overall, 1–2 % of patients experience a paradoxical increase in nightmare intensity or frequency, contrasting with the majority who improve【6】. (Evidence level not specified)

The paradoxical nightmare effect tends to appear early, most often within the first month of therapy (reported in the cited study).
Dose‑dependence is suggested, although precise dose thresholds that trigger the effect have not been established【6】.
Patients already suffering from frequent nightmares (e.g., those with PTSD) may be at higher risk for experiencing a worsening of dream content when treated with trazodone【6】.

While nightmares are a rare adverse event, daytime sedation occurs in about 60 % of tolerating patients, and other side effects such as dizziness and priapism are also reported more frequently than nightmare exacerbation【6】. (Evidence level not specified)